Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute for Health Research, United Kingdom | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Haematological cancer treatment often includes use of high dose glucocorticoids (steroids), chemotherapy and radiotherapy and current evidence suggests that these patients may have lower bone mineral density after treatment when compared to the general population which can predispose them to increased risk of fragility fractures. Evidence of the impact of these musculoskeletal burden to patients (e.g. quality of life) are not available.
This study aims to describe musculoskeletal complications experienced by long-term haematological cancer survivors and examine the impact of the burden from the patient perspective. The study will be conducted in 2 parts; a questionnaire study and an interview study to help understand the extent of musculoskeletal problems experienced by this group of patients and the impact of this on quality of life.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 5-10 years post cancer treatment; male; age at diagnosis 18-30 |
| ||
| 5-10 years post cancer treatment; male; age at diagnosis 31-50 |
| ||
| 5-10 years post cancer treatment; male; age at diagnosis 51-70 |
| ||
| 5-10 years post cancer treatment; male; age at diagnosis 70+ |
| ||
| 5-10 years post cancer treatment; female; age at diagnosis 18-30 |
| ||
| 5-10 years post cancer treatment; female; age at diagnosis 31-50 |
| ||
| 5-10 years post cancer treatment; female; age at diagnosis 51-70 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Not an intervention study | Other | This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors. |
| Measure | Description | Time Frame |
|---|---|---|
| Questionniare study: To measure prevalence of musculoskeletal conditions and related symptoms experienced by adult lymphoma and leukaemia survivors | Musculoskeletal conditions and related symptoms will be recorded by patients on the study specific questionnaire and the validated questionnaire Nordic musculoskeletal questionnaire (NMQ-E) and gait, arms, legs and spine (GALS) assessment | overall length of the study - 6 months |
| Questionniare study: To calculate the 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) of adult lymphoma and leukaemia survivors | The 10-year probability of hip fracture and major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) of adult lymphoma and leukaemia survivors will be calculated using the Fracture Risk Assessment Tool (FRAX) and Q-Fracture calculator. | overall length of the study - 6 months |
| Questionniare study: To measure prevalence of sarcopenia and frailty among adult lymphoma and leukaemia survivors | Validated questionniares will be used to assess if patients have sarcopenia (SARC-F questionnaire) and frailty (FiND questionnaire). | overall length of the study - 6 months |
| Questionniare study: To assess quality of life and musculoskeletal function related quality of life of adult lymphoma and leukaemia survivors | This will be assessed using validated questionnaires - Short Form Survey (SF36) and Short Musculoskeletal Function Assessment (SMFA). | overall length of the study - 6 months |
| Interivew study: To describe experience of adult lymphoma and leukaemia survivors on musculoskeletal health, musculoskeletal related care and musculoskeletal health information provision. | Semi-structured qualitative interviews will be conducted with a topic guide to ensure same broad topics are explored in the interviews on musculoskeletal health experience, care and information provision. |
| Measure | Description | Time Frame |
|---|---|---|
| Questionnaire study: To describe the likely risk factors that may be associated with musculoskeletal consequences of adult lymphoma and leukaemia survivors Impact of musculoskeletal health | This will be assessed using regression analysis to determine risk factors that may be associated with poor musculoskeletal health | overall length of the study - 6 months |
Not provided
Questionnaire study
Inclusion Criteria:
Exclusion Criteria:
1.Currently receiving any active cancer treatment
Interview study
Inclusion Criteria:
Exclusion Criteria:
1 .Currently receiving any active cancer treatment
Not provided
Not provided
Not provided
Participants will be identified from The Christie NHS Foundation Trust local haematology and lymphoma survivors' clinical patient databases. The haematology database used is the HSCT database that records all haematology patients that have undergo haematopoietic stem cell transplant. For lymphoma patients, the ADAPT (Managed Local Follow up of Long-Term Lymphoma Survivors) database will be used which records lymphoma patients that are cured and had 5 years regular hospital follow up post treatment.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Salina Tsui, MSc | Contact | +44 7726781196 | salina.tsui@nhs.net | |
| Claire Higham, PhD | Contact | claire.higham2@nhs.net |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Christie NHS Foundation Trust | Recruiting | Manchester | M20 4BX | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D007938 | Leukemia |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5-10 years post cancer treatment; female; age at diagnosis 70+ |
|
| 11-20 years post cancer treatment; male; age at diagnosis 18-30 |
|
| 11-20 years post cancer treatment; male; age at diagnosis 31-50 |
|
| 11-20 years post cancer treatment; male; age at diagnosis 51-70 |
|
| 11-20 years post cancer treatment; male; age at diagnosis 70+ |
|
| 11-20 years post cancer treatment; female; age at diagnosis 18-30 |
|
| 11-20 years post cancer treatment; female; age at diagnosis 31-50 |
|
| 11-20 years post cancer treatment; female; age at diagnosis 51-70 |
|
| 11-20 years post cancer treatment; female; age at diagnosis 70+ |
|
| 21-30 years post cancer treatment; male; age at diagnosis 18-30 |
|
| 21-30 years post cancer treatment; male; age at diagnosis 31-50 |
|
| 21-30 years post cancer treatment; male; age at diagnosis 51-70 |
|
| 21-30 years post cancer treatment; male; age at diagnosis 70+ |
|
| 21-30 years post cancer treatment; female; age at diagnosis 18-30 |
|
| 21-30 years post cancer treatment; female; age at diagnosis 31-50 |
|
| 21-30 years post cancer treatment; female; age at diagnosis 51-70 |
|
| 21-30 years post cancer treatment; female; age at diagnosis 70+ |
|
| 30 years + post cancer treatment; male; age at diagnosis 18-30 |
|
| 30 years + post cancer treatment; male; age at diagnosis 31-50 |
|
| 30 years + post cancer treatment; male; age at diagnosis 51-70 |
|
| 30 years + post cancer treatment; male; age at diagnosis 70+ |
|
| 30 years + post cancer treatment; female; age at diagnosis 18-30 |
|
| 30 years + post cancer treatment; female; age at diagnosis 31-50 |
|
| 30 years + post cancer treatment; female; age at diagnosis 51-70 |
|
| 30 years + post cancer treatment; female; age at diagnosis 70+ |
|
| overall length of the study - 6 months |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D006402 | Hematologic Diseases |